(secondQuint)A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants.

 This is an open-label (all people know the identity of the intervention), single oral-dose and post-marketing study of darunavir administered in combination with low-dose ritonavir in healthy adult Japanese male participants.

 The total study duration will be approximately of 14 days per participant.

 The study consists of 3 parts: Screening (that is, 28 days before study commences on Day 1); Treatment (that is, Day 1-5); and Follow-up (that is, up to Day 13).

 The participants will be hospitalized for 6 nights and 7 days.

 All the eligible participants will receive Darunavir oral tablet on Day 3 and ritonavir capsule orally twice daily from Day 1-5.

 Participants will keep upright position until 4 hours after study drug administration.

 Both the drugs will be administered within 15 minutes after completion of meal.

 Blood samples will be collected for evaluation of pharmacokinetics at pre-dose and post-dose of study treatment.

 Participants' safety will be monitored throughout the study.

.

 A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants@highlight

The purpose of this study is to evaluate the pharmacokinetics (explores what the body does to the drug) and safety of darunavir, and will be administered in combination with Ritonavir in healthy adult Japanese male participants.

